Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Madelynn N Whittaker

Showing results (1-10 of 14) with videos related to

Pageof 2
Sort By:
Current Opinion in Lipidology|December 15, 2021
Therapeutic application of genome editing in dyslipidemiaMadelynn N Whittaker, Kiran Musunuru
Science (New York, N.Y.)|June 27, 2024
An epigenetic editor to silence genesMadelynn N Whittaker, Kiran Musunuru
Science (New York, N.Y.)|March 29, 2020
Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variantsRussell T Walton, Kathleen A Christie, Madelynn N Whittaker, et al.
American Journal of Human Genetics|November 4, 2023
Efficient in vivo prime editing corrects the most frequent phenylketonuria variant, associated with high unmet medical needDominique L Brooks, Madelynn N Whittaker, Ping Qu, et al.
HGG Advances|November 3, 2023
A base editing strategy using mRNA-LNPs for in vivo correction of the most frequent phenylketonuria variantDominique L Brooks, Madelynn N Whittaker, Hooda Said, et al.
Biorxiv : the Preprint Server for Biology|June 9, 2023
Epigenome Editing Durability Varies Widely Across Cardiovascular Disease Target GenesMadelynn N Whittaker, Lauren C Testa, Aidan Quigley, et al.
JCI Insight|August 30, 2022
Allele-specific silencing of the gain-of-function mutation in Huntington's disease using CRISPR/Cas9Jun Wan Shin, Eun Pyo Hong, Seri S Park, et al.
Biorxiv : the Preprint Server for Biology|May 7, 2024
Improved specificity and efficacy of base-editing therapies with hybrid guide RNAsMadelynn N Whittaker, Dominique L Brooks, Aidan Quigley, et al.
American Journal of Human Genetics|April 2, 2026
Implications of the FDA's new plausible mechanism framework for the development of a personalized in vivo prime editing platformEmily R Feierman, Madelynn N Whittaker, Aidan Quigley, et al.
Nature Communications|August 15, 2023
Treatment of monogenic and digenic dominant genetic hearing loss by CRISPR-Cas9 ribonucleoprotein delivery in vivoYong Tao, Veronica Lamas, Wan Du, et al.
Pageof 2

Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Current Opinion in Lipidology|December 15, 2021
Therapeutic application of genome editing in dyslipidemiaMadelynn N Whittaker, Kiran Musunuru
Science (New York, N.Y.)|June 27, 2024
An epigenetic editor to silence genesMadelynn N Whittaker, Kiran Musunuru
Science (New York, N.Y.)|March 29, 2020
Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variantsRussell T Walton, Kathleen A Christie, Madelynn N Whittaker, et al.
American Journal of Human Genetics|November 4, 2023
Efficient in vivo prime editing corrects the most frequent phenylketonuria variant, associated with high unmet medical needDominique L Brooks, Madelynn N Whittaker, Ping Qu, et al.
HGG Advances|November 3, 2023
A base editing strategy using mRNA-LNPs for in vivo correction of the most frequent phenylketonuria variantDominique L Brooks, Madelynn N Whittaker, Hooda Said, et al.
Biorxiv : the Preprint Server for Biology|June 9, 2023
Epigenome Editing Durability Varies Widely Across Cardiovascular Disease Target GenesMadelynn N Whittaker, Lauren C Testa, Aidan Quigley, et al.
JCI Insight|August 30, 2022
Allele-specific silencing of the gain-of-function mutation in Huntington's disease using CRISPR/Cas9Jun Wan Shin, Eun Pyo Hong, Seri S Park, et al.
Biorxiv : the Preprint Server for Biology|May 7, 2024
Improved specificity and efficacy of base-editing therapies with hybrid guide RNAsMadelynn N Whittaker, Dominique L Brooks, Aidan Quigley, et al.
American Journal of Human Genetics|April 2, 2026
Implications of the FDA's new plausible mechanism framework for the development of a personalized in vivo prime editing platformEmily R Feierman, Madelynn N Whittaker, Aidan Quigley, et al.
Nature Communications|August 15, 2023
Treatment of monogenic and digenic dominant genetic hearing loss by CRISPR-Cas9 ribonucleoprotein delivery in vivoYong Tao, Veronica Lamas, Wan Du, et al.
Pageof 2